Filter
315
Text search:
pfizer
Featured
41
17
Language
Document type
79
73
64
41
16
15
8
5
4
4
3
3
Countries / Regions
14
11
9
9
9
8
7
7
7
6
5
5
5
4
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
104
20
7
6
4
1
1
Toolboxes
154
30
16
15
14
12
8
8
6
4
4
3
3
3
1
1
1
1
21 May 2021. PACK Home: Information and advice for the home
Available in English, Afrikaans and isiXhosa
Este documento de referência foi preparado pelo Grupo de Trabalho sobre Vacinas contra COVID-19 do Grupo Consultivo Estratégico de Especialistas em Imunização (SAGE) para orientar as discussões do SAGE em sua reunião extraordinária de 8 de fevereiro de 2021, que resultou na publicação do do
...
orientations provisoires, 14 juin 2021
Consideraciones para aplicar y ajustar medidas de salud pública y sociales en el contexto de la COVID-19
recommended
orientaciones provisionales, 14 de junio de 2021
module de la série d’évaluation des capacités des services de santé dans le contexte de la pandémie de COVID-19, 7 juillet 2021
medios de diagnóstico, tratamientos y grado de preparación respecto a las vacunas y otros productos sanitarios: módulo de las evaluaciones armonizadas de la capacidad de los centros de salud en el contexto de la pandemia de COVID-19, 7 de julio de 2021
orientations provisoires, première publication: 10 février 2021, mise à jour : 21 avril 2021, dernière mise à jour : 30 juillet 2021
временное руководство. Первый выпуск: 10 февраля 2021 г. Обновлено: 21 апреля 2021 г. Последнее обновление 30 июля 2021г.
El presente protocolo se aplica en las Instituciones Prestadoras de Servicios de Salud del Ministerio de Salud, a través de las Direcciones de Redes Integradas de Servicios de Salud y de los gobiernos regionales, a través de las Direcciones Regionales de Salud o Gerencias Regionales de Salud , EsS
...
National Operationalisation Plan for the COVID-19 Vaccine : 13th edition
21 January 2022
The overall threat posed by Omicron largely depends on four key questions: (i) how transmissible the variant is; (ii) how well vaccines and prior infection protect against infection, transmission, clinical disease and death; (iii) how virulent the variant is compared to other varian
...
This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations about care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of a
...
Interim guidance, 26 October 2021
This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 5 October 2021.
SAGE said moderately and severely immunocompromised persons should be offered an addition
...
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
Lancet Public health 2022 January 6, 2022 https://doi.org/10.1016/ S2468-2667(21)00249-8
Growth in the number of individuals living with dementia underscores the need for public health planning efforts and policy to address the needs of this group. Country-level estimates can be used to inform nati
...
